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Background. Gram-negative (GN) infections in ICU patients have increased antibiotic resistance owing to higher minimum inhibitory concentrations (MICs). Piperacillin/tazobactam (PTZ) 3.375 g extended infusion (EI) may be used as an empiric agent. GN organisms with PTZ MICs > 16/4 may not be adequately covered by this regimen. The objective of this study was to evaluate MICs of GN isolates from the ICU to determine whether PTZ 3.375 g EI is an appropriate empiric regimen for ICU patients. Appropriateness of empiric antibiotic therapy was defined as PTZ MIC ≤16/4 in greater than 80% of isolates. The secondary objective was to evaluate patient specific risk factors that may be associated with elevated PTZ MICs in GN pathogens.
Methods. All ICU patients admitted from January to December 2017 with a confirmed GN pathogen from a non-urinary source were included. Patients were excluded if they had cystic fibrosis, cultures obtained >48 hours prior to ICU admission, or they were incarcerated. Patients' electronic medical records were reviewed for the following data: age, sex, ethnicity, location prior to ICU admission, GN pathogen, culture source, risk factors for multi-drug-resistant organisms (dialysis, injection drug use, indwelling catheter, wounds/trauma), pathogen susceptibility profile, risk modifying co-morbidities (diabetes, heart failure, chronic kidney disease, and liver disease) and creatinine clearance.
Results. 231 patients were included in the study. The average patient was 56.7 years old ±16.95. The majority of patients were white (64.1%) and male (69.7%). There were no significant differences in baseline characteristics between patients with PTZ MICs >16/4 and those with MICs ≤16/4. Pseudomonas aeruginosa (41%) was the primary organism identified and 28% of all GN isolates had MICs >16/4. Dialysis (P = 0.028), IV antibiotics (P < 0.001) and presence of wounds or trauma (P = 0.018) were all associated with elevated MICs.
Conclusion. Current PTZ EI 3.375g dosing may not provide adequate empiric coverage of GN pathogens for ICU patients especially for patients who received previous IV antibiotics, are on dialysis, or have the presence of wounds or trauma.
Disclosures. All authors: No reported disclosures. Background. The treatment of XDR Gram-negative bacilli poses a significant clinical challenge with limited treatment options. Colistin-resistant XRD Gram-negative bacteria are becoming more commonplace in the clinical setting. Combination therapy is resorted to for treatment of such strains. The objective of this in-vitro study was to evaluate the synergistic effect of the combination with COL and MEM against Colistinresistant XDR Gram-negative bacilli.
Evaluation of Meropenem (MEM) in Combination With
Methods. In this study, a total of 30 Colistin-resistant XDR Gram-negative clinical isolates were evaluated, including five isolates of Pseudomonas aeruginosa, twenty-four isolates of Acinetobacter baumannii and one isolate of Klebsiella pneumonia. Minimum inhibitory concentrations (MICs) were determined with COL and MEM for each strain by broth microdilution. COL and MEM MICs were measured in the presence of 0.25-to 0.5-× the MIC of the other antibiotic to determine the ability to lower MIC values. Time-kill assays were performed with each agent alone and in combination to evaluate the potential for synergistic interactions. Additive and synergistic effects were defined as 1-to 2-log 10 and ≥ 2-log 10 reductions in CFU/mL from the most active single agent at 24 hours, respectively.
Results. All isolates were resistant to COL (MIC90 32 mg/L), whereas all bacteria with except one A. baumannii, were resistant to MEM (MIC90 >64 mg/L). Zero-to greater than nine-fold decrease in MEM MICs were observed in combination with COL at 0.25-to 0.5 × MIC. COL MICs decreased by 0 to >8-fold when combined with MEM. MEM plus COL demonstrated synergistic activity against 70% strains tested and additive in 3% of the tested strains at 24 h in time-kill. The combination was indifferent in 26% of the tested strains.
Conclusion. These data indicate that the addition of MEM to COL therapy in colistin resistant XDR Gram-negative bacteria demonstrate synergistic or additive effects against a majority of XDR Gram-negative bacteria. The combination might be a promising therapeutic option for treatment of these problem pathogens. 
